Our funding

The EHC needs funds to pursue its mission on behalf of people with rare bleeding disorders. The EHC National Member Organisations pay an annual membership fee determined by the General Assembly. Besides, the EHC receives also external funding support from both public and private organisations.

content-logo-colorfull

Annual Financial Reporting

The EHC General Assembly meets annually and approves the organisation’s Annual Report, containing our most recent financial report. The EHC’s accounts are also audited yearly and submitted to the Belgian commercial court for publication.

Corporate Partners

The EHC accepts financial and non-monetary support with the mutual understanding that the EHC maintains its independence and makes choices based exclusively on patients’ needs and interests. The EHC follows a strict Policy on Financial Support from Corporate Sponsors and observes strict EHC Funding Practices and Principles.

In 2025, the EHC had a total of 13 pharma sponsors, supporting its overall operations from 1% to 19%.

The EHC gratefully acknowledges members of the EHC’s 2026 Corporate Giving Programme (GCP). 

 


Elite Level

Platinum Level

Gold Level

Silver Level

Sponsor Acknowledgements

The EHC wishes to thank the following companies for supporting the following platforms in 2026:

  • The European Rare and Inhibitor Network (ERIN) Platform is supported by Kedrion, Roche, and Sanofi
  • The Patient Education Platform is supported by CSL Behring, Novo Nordisk, and Sobi
  • The von Willebrand Disease (VWD) Platform is supported by Roche and Takeda
  • The Women and Bleeding Disorders (WBD) Platform is supported by Roche
  • The Youth Platform is supported by Sanofi